NDASUBLINGUALTABLET
Approved
Aug 2009
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
4/8 — Partial
SAPHRIS (asenapine maleate) by AbbVie is asenapine, in schizophrenia and bipolar i disorder, is unknown. First approved in 2009.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAPHRIS (asenapine maleate) is a sublingual atypical antipsychotic approved in 2009 for schizophrenia and bipolar I disorder. It works via antagonism at dopamine D2 and serotonin 5-HT2A receptors, though its exact mechanism remains incompletely understood. The sublingual formulation offers rapid onset compared to oral alternatives.
$9MPart D
LOE ApproachingDeclining
3mo to LOEProduct is in late-stage lifecycle with minimal growth opportunity; commercial team is likely focused on defense against generics and maintaining specialty segment presence.
Mechanism of Action
asenapine, in schizophrenia and bipolar I disorder, is unknown. It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D 2 and 5-HT 2A receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on SAPHRIS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.